香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） （股份代號：1521） 與2022年年報有關的 補充公告 茲提述方達控股公司（「本公司」，連同其附屬公司，「本集團」）截至2022年12月 31日止年度的年報（「2022年年報」）。除另有說明外，本公告所用詞彙與2022年年 報所用者俱有相同涵義。 本公司於2021年1月22日採納2021年股份獎勵計劃。截至2022年12月31日止年 度，根據2021年股份獎勵計劃，合共5,362,374股獎勵股份已歸屬承授人。有關根 據2021年股份獎勵計劃授出的獎勵股份的變動詳情，請參閱2022年年報「董事會 報告」一節「2021年股份獎勵計劃」一段。 就2022年年報所披露的2021年股份獎勵計劃而言，本公司謹此補充，本公司於財 政年度內緊接獎勵歸屬日期前股份的加權平均收市價為3.90港元。 除本公告所披 ...

Financial Performance - Revenue for 2022 reached $250.36 million, a 35.7% increase from $184.44 million in 2021[4] - Gross profit for 2022 was $89.19 million, representing a gross margin of 35.6%[4] - Adjusted net profit for 2022 was $36.17 million, up from $32.24 million in 2021, reflecting a 12.1% increase[4] - The company reported a net profit margin of 10.3% for 2022, consistent with the previous year[4] - The company's net profit increased by 37.0% from approximately $18.9 million in 2021 to approximately $25.9 million in 2022, maintaining a net profit margin of 10.3%[43] - Adjusted net profit increased by 12.4% from approximately $32.2 million in 2021 to approximately $36.2 million in 2022, with an adjusted net profit margin of 14.4% compared to 17.5% in 2021[45] - EBITDA rose by 35.5% from approximately $51.6 million in 2021 to approximately $69.9 million in 2022, with an EBITDA margin of 27.9% compared to 28.0% in 2021[46] - Adjusted EBITDA increased by 20.4% from approximately $60.8 million in 2021 to approximately $73.2 million in 2022, with an adjusted EBITDA margin declining from 33.0% to 29.3%[47] Assets and Liabilities - Total assets as of December 31, 2022, amounted to $550.59 million, compared to $475.84 million in 2021[4] - Total liabilities increased to $214.75 million in 2022 from $152.76 million in 2021[4] - Cash and cash equivalents decreased to $87.43 million in 2022 from $144.63 million in 2021[4] - Property, plant, and equipment increased by 26.8% from approximately $90.7 million in 2021 to approximately $115.0 million in 2022, driven by R&D and manufacturing capacity expansion[50] - Goodwill increased by 108.7% from approximately $71.5 million in 2021 to approximately $149.2 million in 2022, primarily due to the acquisition of Experimur and Clinical[52] Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new technologies[4] - Future guidance indicates a focus on increasing revenue through new product development and potential acquisitions[4] - The company aims to improve its adjusted net profit margin by optimizing operational efficiencies[4] - The company completed the acquisition of Experimur LLC and Frontage Clinical Services Inc., enhancing its capabilities and expanding into new research areas[8] - The company plans to expand its service capabilities through internal growth and acquisitions, focusing on key areas such as cell and gene therapy in 2023[10] - The company established a global project management team to manage clinical trials and provide logistical support for global pharmaceutical companies[16] Operational Developments - A new laboratory facility of approximately 25,000 square feet in Hayward, California, commenced operations in May 2022, significantly improving the company's bioanalytical and biomanufacturing service capabilities[9] - The company’s new API production facility in Weihai, China, has completed Phase I construction, covering 120,000 square feet and equipped with reactors totaling 50,000 liters[9] - The establishment of a frozen biorepository in Exton, Pennsylvania, supports clinical trial research with over forty -20°C and -70°C freezers[16] - The company enhanced its capabilities in targeted nucleic acid analysis and next-generation sequencing (NGS) during the reporting period[16] Employee and Workforce - The company has a workforce of 1,698 employees across over 23 locations in three countries as of December 31, 2022[9] - Employee costs for the fiscal year ended December 31, 2022, were approximately $102.9 million, compared to $73.7 million for the fiscal year ended December 31, 2021, indicating a rise of 39.6%[59] - Approximately 80% of the company's employees hold a bachelor's degree or higher, with 556 employees holding advanced degrees[59] Governance and Leadership - The company has a strong leadership team with diverse backgrounds in pharmaceuticals, finance, and investment banking, enhancing its strategic decision-making capabilities[66] - The board believes that the directors can dedicate sufficient time and effort to fulfill their responsibilities as independent non-executive directors, ensuring effective governance[66] - The company is committed to maintaining high professional standards in its board meetings and committee activities, ensuring accountability and transparency[66] - The board consists of seven directors, including a balanced mix of executive and independent non-executive directors[166] Risk Management - Key operational risks include dependency on client demand for outsourcing services, which is influenced by clients' financial performance and R&D spending[129] - Business risks include potential loss of contracts, inability to convert backlog into revenue, and financial risks from underestimating fixed-price contracts[130] - The company faces additional risks related to its acquisition strategy, including the ability to realize expected synergies and manage financial risks associated with debt[131] - The company has implemented various risk management procedures and guidelines to manage risks across key business processes, including financial reporting and compliance[194] Compliance and Regulatory - The company has established compliance policies and procedures to ensure adherence to applicable laws and regulations, with no known violations during the reporting period[151] - The company has adopted a standard code for securities trading by directors, confirming compliance during the reporting period[154] - The company has received annual confirmations of independence from all independent non-executive directors[85] Shareholder Information - As of December 31, 2022, the total distributable reserves available for shareholders amounted to approximately $97.3 million[81] - The group did not declare any final dividend for the reporting period[78] - The company has adopted a dividend policy to ensure sufficient reserves for future growth while allowing shareholders to participate in profit distribution[78] IPO and Financial Activities - The company raised approximately $193.2 million from its IPO, with a remaining unutilized net amount of about $11.6 million as of December 31, 2022[145] - 20% of the IPO proceeds, amounting to $38.6 million, was allocated to expand and enhance existing capacity to meet anticipated service demand[146] - The company reported a total of $181.6 million in actual utilization of IPO proceeds by December 31, 2022[146] Environmental and Social Responsibility - The company is committed to environmental responsibility and will implement further environmental measures to enhance sustainability[152] - The company values its employees as important assets and provides competitive compensation and training to enhance their understanding of corporate values[155]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 董事會不建議就報告期內派付任何末期股息。 1 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） （股份代號：1521) 全年業績公告 截至2022年12月31日止年度 | --- | --- | --- | --- | --- | |---------------------------------------------------------|--------|--------------------|--------------------|-------| | | | | | | | 財務摘要 | | 2022 年 百萬美元 | 2021 年 百萬美元 | 變動 | | 收益 | | 250.4 | 184.4 | 35.8% | | 毛利 毛利率 | | 89.2 35.6% | 66.7 36.2% | 33.7% | | 稅息折舊 ...

Frontage Holdings Corporation 方達控股公司 * （於開曼群島註冊成立的有限公司） 股份代號 : 1521 2021 年 度 報 告 * 僅供識別 前瞻性陳述 本年報載有若干前瞻性陳述或使用若干前瞻性詞彙的若干陳述。該等前瞻性陳述乃基於董事 會有關其經營所在行業及市場的信念、假設及期望，並且存在非本公司所能控制的風險、不 明朗因素及其他因素，從而可能令實際結果或表現與該等前瞻性陳述中明示或暗示的情況有 重大差別。 2021年度報告 2 公司資料 董事會 執行董事 李松博士 （行政總裁兼主席） 李志和博士 非執行董事 高峻先生 獨立非執行董事 李軼梵先生 劉二飛先生 王勁松博士 審核及風險管理委員會成員 李軼梵先生 （主席） 劉二飛先生 高峻先生 薪酬委員會成員 王勁松博士 （主席） 李軼梵先生 李松博士 提名委員會成員 王勁松博士 （主席） 劉二飛先生 李松博士 公司秘書 張盈倫女士 （香港律師） 授權代表 李志和博士 張盈倫女士 核數師 香港立信德豪會計師事務所有限公司 執業會計師 主要往來銀行 Wells Fargo Bank, N.A. 法律顧問 有關香港法律： Morgan ...